Stockscreener 앱 받기
139.34
3.82%
-5.54
시간 외 거래:
139.09
-0.25
-0.18%
전일 마감가:
$144.88
열려 있는:
$140.65
하루 거래량:
443.63K
Relative Volume:
0.76
시가총액:
$8.13B
수익:
$633.51M
순이익/손실:
$-8.10M
주가수익비율:
-449.48
EPS:
-0.31
순현금흐름:
$131.26M
1주 성능:
-2.18%
1개월 성능:
-14.34%
6개월 성능:
-2.54%
1년 성능:
-29.17%
1일 변동 폭
$137.92
$144.32
1주일 범위
$137.92
$153.89
52주 변동 폭
$113.50
$200.23
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
RGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
139.34 | 8.13B | 633.51M | -8.10M | 131.26M | -0.31 |
|
ISRG
Intuitive Surgical Inc
|
491.81 | 176.29B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
231.85 | 66.57B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.37 | 45.19B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
221.11 | 32.48B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.44 | 17.07B | 17.28B | 108.00M | 391.00M | 0.20 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
PNC Financial Services Group Inc. Sells 262 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corp director Hunt Anthony sells $4.08 million in stock By Investing.com - Investing.com South Africa
Repligen Corp director Hunt Anthony sells $4.08 million in stock - Investing.com
Repligen’s SWOT analysis: bioprocessing leader’s stock faces growth and valuation challenges - Investing.com
Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI - Defense World
Repligen Co. (NASDAQ:RGEN) Shares Sold by Victory Capital Management Inc. - Defense World
Repligen director Pax Margaret acquires $37,672 in common stock By Investing.com - Investing.com Australia
REPLIGEN Director Margaret Pax Acquires 250 Shares - TradingView
Evercore ISI sets Repligen stock In Line with $155 price target - Investing.com
Demystifying Repligen: Insights From 6 Analyst Reviews - Benzinga
Repligen initiated with an In Line at Evercore ISI - TipRanks
Repligen Corp (RGEN) Shares Up 5.72% on Mar 17 - GuruFocus.com
Repligen Corp (RGEN) Shares Up 5.72% on Mar 15 - GuruFocus.com
REPLIGEN CORP SEC 10-K Report - TradingView
William Blair Brokers Reduce Earnings Estimates for Repligen - Defense World
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack - The Globe and Mail
Oppenheimer & Co. Inc. Purchases New Shares in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen Corporation’s Acquisition of Bioprocessing PAT Device Portfolio from 908 Devices - Global Legal Chronicle
US Bancorp DE Raises Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen buying 908 Devices’ Bioprocess Analytics portfolio - BioWorld Online
Sanctuary Advisors LLC Sells 268 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen (NASDAQ:RGEN) and Compass Therapeutics (NASDAQ:CMPX) Critical Review - Defense World
Truist Financial Corp Trims Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - AOL
Leerink maintains Repligen stock Outperform rating, $200 target - Investing.com
908 Devices stock jumps on Repligen deal (RGEN:NASDAQ) - Seeking Alpha
Repligen acquires 908 Devices’ desktop bioprocessing tech - Investing.com
Repligen acquires 908 Devices’ desktop bioprocessing tech By Investing.com - Investing.com Canada
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Yahoo Finance
Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Repligen Co. (NASDAQ:RGEN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Global Retirement Partners LLC Has $53,000 Stock Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Global Hollow Fiber Filtration Market: A Comprehensive Study - openPR
CIBC Asset Management Inc Acquires 81 Shares of Repligen Co. (NASDAQ:RGEN) - Defense World
Principal Financial Group Inc. Decreases Position in Repligen Co. (NASDAQ:RGEN) - Defense World
Repligen’s SWOT analysis: bioprocessing leader’s stock poised for growth - Investing.com
Repligen stock holds steady after Benchmark maintains rating - Investing.com
Repligen stock holds steady after Benchmark maintains rating By Investing.com - Investing.com UK
Repligen (NASDAQ:RGEN) Price Target Raised to $200.00 - Defense World
Repligen (NASDAQ:RGEN) Price Target Raised to $205.00 - Armenian Reporter
Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World
Repligen (NASDAQ:RGEN) Earns Buy Rating from HC Wainwright - Defense World
Repligen (NASDAQ:RGEN) Shares Up 8.1% Following Strong Earnings - Defense World
Repligen Earnings: Encouraging Guidance Supports Attractive Growth Story - Morningstar
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Repligen (RGEN) Beats Q4 Earnings Estimates - MSN
Repligen's Q4 Earnings Beat Estimates, Revenues In Line - Yahoo Finance
The Analyst Verdict: Repligen In The Eyes Of 4 Experts - Benzinga
H.C. Wainwright maintains Buy on Repligen, target at $180 - Investing.com
Repligen Corporation (NASDAQ:RGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Canaccord raises Repligen stock target to $170, maintains Hold - Investing.com
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.34%
1.61%
자본화:
|
볼륨(24시간):